<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-110775</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Candida sp endocarditis. Experience in a thirdlevel hospital and review of the literature</dc:title>
<dc:description xml:lang="en">Despite the relative high frequency of Candida bloodstream infection, Candida endocarditis is a rare entity. We report five cases of Candida endocarditis admitted to our hospital in the period between 2005 and 2011. Two cases were caused by C. albicans, two cases were caused by C. parapsilosis and in the last one, we didn´t identify the species of Candida. All but one had clear risk factors for candidemia. Treatment consisted of amphotericin B with / without flucytosine in four patients, and they all underwent surgery for valve replacement and / or removal of intravascular devices. Overall mortality was 60% (40% of mortality was directly related to endocarditis). All patients who survived were given suppressive therapy with fluconazole for a minimum of two years.After stopping fluconazole there was a case of recurrence(AU)</dc:description>
<dc:creator>García-Vázquez, Elisa</dc:creator>
<dc:creator>Laso-Ortiz, Alicia</dc:creator>
<dc:creator>Herrero-Martínez, José Antonio</dc:creator>
<dc:creator>Gómez-Gómez, Joaquín</dc:creator>
<dc:creator>Hernández-Torres, Alicia</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">A pesar de la relativa alta frecuencia de candidemia, la endocarditis por Candida sp es una entidad rara. Describimos cinco casos de endocarditis por Candida ingresados en nuestro hospital en el período comprendido entre los años 2005-2011. Dos de los casos estaban causados por Candida albicans, dos por Candida parapsilosis, y en otro de ellos no se identificó la especie de Candida. Todos ellos, salvo uno, presentaban claros factores de riesgo de candidemia. El tratamiento consistió en anfotericina B con/sin flucitosina en cuatro de los pacientes, y en todos ellos se realizó cirugía de sustitución valvular y/o extracción de los dispositivos intravasculares. La mortalidad global fue del 60%, y en un 40% fue directamente relacionada con la endocarditis. A todos los pacientes que sobrevivieron se les administró tratamiento supresor con fluconazol durante un mínimo de dos años, tras cuya suspensión hubo un caso de recidiva(AU)</dc:description>
<dc:source>Rev Esp Quimioter;26(1): 51-55, mar.2013.</dc:source>
<dc:identifier>ibc-110775</dc:identifier>
<dc:title xml:lang="es">Endocarditis por Candida sp. Experiencia en un hospital terciario y revisión de la literatura</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d24654^s22073</dc:subject>
<dc:subject>^d28621</dc:subject>
<dc:subject>^d5570^s22073</dc:subject>
<dc:subject>^d4777^s22012</dc:subject>
<dc:subject>^d4777^s22057</dc:subject>
<dc:subject>^d4777^s22046</dc:subject>
<dc:subject>^d52634^s22012</dc:subject>
<dc:subject>^d4777^s22016</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30421^s22001</dc:subject>
<dc:subject>^d23255^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d2207^s22021</dc:subject>
<dc:subject>^d2207^s22001</dc:subject>
<dc:subject>^d27953^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:type>article</dc:type>
<dc:date>201303</dc:date>
</metadata>
</record>
</ibecs-document>
